Mind Medicine (MindMed) Inc. (MNMD)
Automate Your Wheel Strategy on MNMD
With Tiblio's Option Bot, you can configure your own wheel strategy including MNMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MNMD
- Rev/Share 0.0
- Book/Share 2.6192
- PB 2.5733
- Debt/Equity 0.0989
- CurrentRatio 7.2734
- ROIC -0.4651
- MktCap 509229040.0
- FreeCF/Share -1.0779
- PFCF -5.5537
- PE -7.3861
- Debt/Assets 0.08
- DivYield 0
- ROE -0.3344
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MNMD | Evercore ISI | -- | Outperform | -- | $23 | Jan. 28, 2025 |
| Initiation | MNMD | Chardan Capital Markets | -- | Buy | -- | $20 | Dec. 20, 2024 |
| Resumed | MNMD | Leerink Partners | -- | Outperform | -- | $20 | Oct. 14, 2024 |
News
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Read More
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive Officer Matt Wiley - Chief Commercial Officer Dan Karlin - Chief Medical Officer Conference Call Participants Madhu Yennawar - Leerink Partners Brian Abrahams - RBC Capital Markets Elaine Kim - Cantor Rudy Li - Chardan Sumant Kulkarni - Canaccord Genuity Michael Okunewitch - Maxim Group Operator Good morning, and welcome to the MindMed's First Quarter 2025 Financial Results and Corporate Update Webcast. Currently, all participants are in listen-only mode.
Read More
Why Mind Medicine Stock Is Skyrocketing Today
Published: February 14, 2025 by: The Motley Fool
Sentiment: Positive
Mind Medicine (MNMD 15.66%) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m.
Read More
About Mind Medicine (MindMed) Inc. (MNMD)
- IPO Date 2016-11-15
- Website https://www.mindmed.co
- Industry Biotechnology
- CEO Robert Barrow
- Employees 74